Literature DB >> 11479219

Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

M Kavallaris1, A S Tait, B J Walsh, L He, S B Horwitz, M D Norris, M Haber.   

Abstract

Vinca alkaloids are used extensively in the treatment of childhood acute lymphoblastic leukemia (ALL) and despite their usefulness, drug resistance remains a serious clinical problem. Vinca alkaloids bind to the beta-tubulin subunit of the alpha/beta-tubulin heterodimer and inhibit polymerization of microtubules. Recent studies have implicated altered beta-tubulin isotype expression and mutations in resistance to microtubule-stabilizing agents. Microtubule-associated protein (MAP) MAP4 binds to and stabilizes microtubules, and increased expression is associated with decreased sensitivity to microtubule-depolymerizing agents. To address the significance of beta-tubulin and MAP4 alterations in childhood ALL, two CCRF-CEM-derived Vinca alkaloid resistant cell lines, VCR R (vincristine) and VLB100 (vinblastine), were examined. Decreased expression of class III beta-tubulin was detected in both VCR R and VLB100 cells. VCR R cells and to a lesser extent VLB100 cells expressed increased levels of MAP4 protein. Increased microtubule stability was observed in these VCR R cells as identified by the high levels of polymerized tubulin (45.6 +/- 2.6%; P < 0.005) compared with CEM and VLB100 cells (24.7 +/- 3.3% and 24.7 +/- 2.5%, respectively). Expression was associated with a single MAP4 isoform in the polymerized microtubule fraction in CEM and VCR cells. In contrast, VLB100 cells expressed a lower molecular weight isoform in the polymerized fraction. Two-dimensional-PAGE and immunoblotting revealed marked posttranslational changes in class I beta-tubulin in VCR R cells not evident in CEM cells. Sequencing of the beta-tubulin (HM40) gene identified a point mutation in VCR R cells in nucleotide 843 (CTC-->ATC; Leu(240)-->Ile) that was not present in CEM or VLB100 cells. This mutation resides in a region of beta-tubulin that lies in close proximity to the alpha/beta tubulin interface. Multiple alterations related to normal microtubule function were identified in ALL cells selected for resistance to Vinca alkaloids, and these alterations may provide important insight into mechanisms mediating resistance to Vinca alkaloids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  Mechanisms of Taxol resistance related to microtubules.

Authors:  George A Orr; Pascal Verdier-Pinard; Hayley McDaid; Susan Band Horwitz
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 2.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

3.  Structural evidence for cooperative microtubule stabilization by Taxol and the endogenous dynamics regulator MAP4.

Authors:  Hui Xiao; Hui Wang; Xuechun Zhang; Zongcai Tu; Chloë Bulinski; Marina Khrapunovich-Baine; Ruth Hogue Angeletti; Susan Band Horwitz
Journal:  ACS Chem Biol       Date:  2012-02-06       Impact factor: 5.100

4.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

5.  Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin.

Authors:  Rundi Ma; Gang Song; Wenbing You; Lijian Yu; Weiming Su; Mingneng Liao; Yongping Zhang; Laizhen Huang; Xiaoyu Zhang; Tingxi Yu
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-21       Impact factor: 3.333

Review 6.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

7.  CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.

Authors:  Chang Hoon Moon; Seung Ju Lee; Ho Yong Lee; Le Thi Kim Dung; Wha Ja Cho; HeeJeong Cha; Jeong Woo Park; Young Joo Min
Journal:  Invest New Drugs       Date:  2013-11-08       Impact factor: 3.850

Review 8.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

9.  Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.

Authors:  Yuefang Wang; Aurora O'Brate; Wei Zhou; Paraskevi Giannakakou
Journal:  Cell Cycle       Date:  2005-12-18       Impact factor: 4.534

10.  Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes.

Authors:  Tyler Luchko; J Torin Huzil; Maria Stepanova; Jack Tuszynski
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.